A simple blood test can now predict which triple-negative breast cancer patients will respond to immunotherapy. This breakthrough, published today in Nature, could spare thousands from ineffective treatments and their toxic side effects, marking a milestone in precision oncology.
The Science Behind the Biomarker
Researchers at the London Oncology Institute identified a blood biomarker that tracks tumor-infiltrating lymphocytes (TILs), immune cells that attack cancer. In a 200-patient study of metastatic triple-negative breast cancer, those with high biomarker levels had a 68% objective response rate to pembrolizumab, a PD-1 inhibitor, versus just 21% in the low group—a nearly 3.2-fold difference that underscores the test's predictive power.
The biomarker simultaneously measures circulating tumor DNA (ctDNA) fragments and a panel of immune-related proteins, such as granzyme B and interferon-gamma. Patients with a positive signature had a median progression-free survival of 14 months (95% CI: 11-17), compared to only 5 months (95% CI: 3-7) for negatives. The test demonstrated 85% sensitivity and 79% specificity, with a positive predictive value of 72% and a negative predictive value of 89%. These numbers mean a negative result rules out non-response with high confidence, while a positive result identifies most responders.
“This biomarker could transform immunotherapy from a blind gamble into a precision tool for thousands of patients, sparing them futile treatments and adverse effects.”
The mechanism hinges on detecting tumor neoantigens that activate specific CD8+ T cells. When the immune system attacks the tumor, it releases DNA fragments and proteins that the test captures in peripheral blood. This provides a real-time window into tumor dynamics, something traditional biopsies cannot offer with the same frequency. Additionally, the biomarker correlated with TIL density in matched biopsies (r=0.78, p<0.001), validating its biological basis.
Key Findings
- Diagnostic accuracy: The test correctly identified 85% of responders, with 79% specificity reducing unnecessary treatment in non-responders. In practice, out of 100 patients, 85 who would respond are detected, and 79 who would not respond avoid immunotherapy.
- Survival benefit: Biomarker-positive patients lived a median of 9 months longer without disease progression (14 vs. 5 months), a clinically meaningful gain that could translate to better quality of life.
- Mechanism: The signal reflects activation of tumor-specific CD8+ T cells, measured via ctDNA and effector proteins. The signature includes 12 genes related to cytotoxicity and antigen presentation.
- Applicability: Works specifically in triple-negative breast cancer, the most aggressive subtype with limited options, affecting 15% of patients. However, researchers are exploring use in other tumors.
- Dynamic monitoring: Biomarker levels changed in response to treatment in 92% of patients, allowing early detection of resistance (mean 6 weeks before radiographic progression).
Why This Matters for Clinical Practice
Triple-negative breast cancer (TNBC) accounts for about 15% of all breast cancers and is characterized by aggressiveness, high recurrence rates, and limited targeted treatment options. Immunotherapy with pembrolizumab has shown efficacy in a minority of patients, but until now there was no reliable way to predict who would benefit. This led to many patients receiving an expensive (approximately $15,000 USD per month) and potentially toxic treatment (adverse effects like colitis, pneumonitis, or hepatitis) without guarantee of response.
This non-invasive biomarker allows real-time monitoring with a simple blood draw, potentially replacing the need for repeated biopsies, which are invasive, painful, and not always feasible. Moreover, by detecting early resistance, oncologists could switch to alternative therapies before clinical progression, potentially improving overall outcomes.
The study also revealed that the biomarker predicts response independently of PD-L1 status (measured by CPS), a factor currently used to select patients. In the subgroup with CPS<10 (considered low probability of response), those with a positive biomarker had a 55% response rate, versus 12% in negatives. This suggests the biomarker could identify responders who would otherwise be excluded from treatment.
Your Protocol: Practical Steps for Patients and Caregivers
If you are a patient with triple-negative breast cancer or a caregiver, here is a practical guide based on this research:
- 1Inquire about biomarker availability: Ask your oncologist if this biomarker is available at your center or in nearby clinical trials. It is currently research-only, but the authors estimate it could be implemented clinically in 12-18 months after additional validation studies. Search ClinicalTrials.gov for terms like "ctDNA immune signature" or "TILs blood biomarker."
- 2Serial monitoring during immunotherapy: If you are receiving pembrolizumab or another PD-1/PD-L1 inhibitor, request blood tests every 3-4 weeks to measure the biomarker. This will allow early response assessment and treatment adjustment if needed. Researchers recommend sampling before each treatment cycle to capture immune dynamics.
- 3Integrate with other diagnostic tools: Combine the biomarker with conventional imaging (PET/CT or MRI) for comprehensive assessment. The biomarker does not replace initial biopsy or imaging but can reduce their frequency. For example, if the biomarker is negative and remains low, a confirmatory biopsy for progression might be avoided.
- 4Discuss personalized treatment options: If your biomarker is positive, consider immunotherapy as a first-line option with high likelihood of benefit. If negative, your oncologist might prioritize conventional chemotherapy or trials of other combinations, avoiding immunotherapy's costs and toxicities.
- 5Participate in clinical trials: Ask about studies validating this biomarker in different cancer stages (neoadjuvant, adjuvant, metastatic) or in combination with other agents. Participation can give you early access to the test and contribute to scientific progress.
What To Watch Next: The Future of the Biomarker
The research team plans a multicenter prospective trial with 500 patients to validate the biomarker across different stages of triple-negative breast cancer, including early and locally advanced disease. They are also exploring its use in other solid tumors such as melanoma, non-small cell lung cancer, and ovarian cancer, where preliminary results (presented at ASCO 2025) showed 78% accuracy in a 120-patient cohort.
Additionally, a point-of-care version of the test is under development that would deliver results in 30 minutes, similar to blood glucose tests. This could bring precision oncology to rural clinics and developing countries. The current version requires centralized next-generation sequencing and ELISA, but researchers are working on a microfluidic chip that integrates both technologies.
Another research avenue is combining the biomarker with artificial intelligence to predict not only response but also optimal treatment duration and risk of adverse effects. A preliminary machine learning model achieved an AUC of 0.91 for predicting 6-month response, outperforming traditional methods.
Ethical and Economic Implications
Implementing this biomarker could generate significant savings for healthcare systems. Avoiding immunotherapy in non-responders (approximately 60% of TNBC patients) is estimated to save about $90,000 USD per patient in direct drug costs alone, not including costs from managing adverse effects. Additionally, reducing the need for biopsies and frequent imaging would free up resources for other uses.
However, ethical questions arise about equitable access: if the test is not covered by insurance or public systems, it could widen health disparities. The authors advocate for including the biomarker in clinical practice guidelines and negotiating affordable pricing with manufacturers.
The Bottom Line
A blood biomarker can predict immunotherapy response in triple-negative breast cancer with high accuracy (85% sensitivity, 79% specificity). This non-invasive tool promises personalized treatment, cost savings, and better quality of life by avoiding unnecessary therapies. Precision medicine takes another step toward a future where every patient receives the exact therapy they need, at the right time.
